IL99761A0 - Purified immunoglobulins,their preparation and pharmaceutical compositions containing them - Google Patents

Purified immunoglobulins,their preparation and pharmaceutical compositions containing them

Info

Publication number
IL99761A0
IL99761A0 IL99761A IL9976191A IL99761A0 IL 99761 A0 IL99761 A0 IL 99761A0 IL 99761 A IL99761 A IL 99761A IL 9976191 A IL9976191 A IL 9976191A IL 99761 A0 IL99761 A0 IL 99761A0
Authority
IL
Israel
Prior art keywords
antibody
column
prepn
cdw52
purified
Prior art date
Application number
IL99761A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL99761(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to IL102726A priority Critical patent/IL102726A0/xx
Publication of IL99761A0 publication Critical patent/IL99761A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL99761A 1990-10-17 1991-10-16 Purified immunoglobulins,their preparation and pharmaceutical compositions containing them IL99761A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL102726A IL102726A0 (en) 1990-10-17 1992-08-04 Purified immunoglobulins,their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (1)

Publication Number Publication Date
IL99761A0 true IL99761A0 (en) 1992-08-18

Family

ID=10683866

Family Applications (3)

Application Number Title Priority Date Filing Date
IL99761A IL99761A0 (en) 1990-10-17 1991-10-16 Purified immunoglobulins,their preparation and pharmaceutical compositions containing them
IL10272691A IL102726A (en) 1990-10-17 1991-10-16 Purified immunoglobulins, their preparation and pharmaceutical compositions containing them
IL102726A IL102726A0 (en) 1990-10-17 1992-08-04 Purified immunoglobulins,their preparation and pharmaceutical compositions containing them

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL10272691A IL102726A (en) 1990-10-17 1991-10-16 Purified immunoglobulins, their preparation and pharmaceutical compositions containing them
IL102726A IL102726A0 (en) 1990-10-17 1992-08-04 Purified immunoglobulins,their preparation and pharmaceutical compositions containing them

Country Status (29)

Country Link
US (1) US5644036A (enExample)
EP (1) EP0504363B2 (enExample)
JP (1) JP2638680B2 (enExample)
KR (2) KR960015399B1 (enExample)
AT (2) ATE162552T1 (enExample)
AU (3) AU658926B2 (enExample)
BE (1) BE1004226A5 (enExample)
BR (1) BR1100358A (enExample)
CA (1) CA2069481C (enExample)
CH (2) CH681305A5 (enExample)
DE (1) DE69128774T3 (enExample)
DK (1) DK0504363T4 (enExample)
ES (2) ES2112865T5 (enExample)
FI (2) FI110003B (enExample)
FR (2) FR2668164A1 (enExample)
GB (2) GB9022547D0 (enExample)
GR (3) GR910100425A (enExample)
HU (1) HUT64601A (enExample)
IE (1) IE913560A1 (enExample)
IL (3) IL99761A0 (enExample)
IT (1) IT1250064B (enExample)
LU (1) LU88122A1 (enExample)
MX (1) MX9203794A (enExample)
MY (2) MY136210A (enExample)
NZ (2) NZ240247A (enExample)
PT (2) PT99248B (enExample)
TW (1) TW283710B (enExample)
WO (1) WO1992007084A1 (enExample)
ZA (2) ZA918259B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0610447B1 (en) * 1991-10-15 1998-12-16 Btg International Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
DE69626022T3 (de) † 1995-08-01 2008-05-08 Sanofi Pasteur Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
ES2266535T3 (es) * 2001-06-05 2007-03-01 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
ES2626268T3 (es) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
EP2314603A3 (en) 2002-10-15 2011-05-18 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
DK1869065T3 (da) * 2005-03-11 2020-06-08 Wyeth Llc Fremgangsmåde til kromatografi med svag opdeling
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010132683A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
JP5873016B2 (ja) 2010-06-21 2016-03-01 協和発酵キリン株式会社 アミノ酸を利用したタンパク質の精製方法
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102344170B1 (ko) 2013-12-27 2021-12-27 추가이 세이야쿠 가부시키가이샤 등전점이 낮은 항체의 정제방법
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2017022651A1 (ja) 2015-07-31 2017-02-09 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3950099A4 (en) 2019-03-29 2022-05-18 Asahi Kasei Medical Co., Ltd. PROTEINS PURIFICATION PROCEDURES
CN113692420B (zh) 2019-04-08 2023-09-12 旭化成医疗株式会社 用于纯化含蛋白质的溶液的聚酰胺介质及其制造方法
AU2020273072B2 (en) 2019-04-10 2026-01-22 Chugai Seiyaku Kabushiki Kaisha Method for purifying Fc region-modified antibody
JPWO2022260091A1 (enExample) 2021-06-10 2022-12-15

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.

Also Published As

Publication number Publication date
GR910100425A (el) 1992-09-25
ATE162552T1 (de) 1998-02-15
ITRM910788A1 (it) 1993-04-16
JPH05504579A (ja) 1993-07-15
DK0504363T3 (da) 1998-09-21
GR920100471A (el) 1994-06-30
FR2677997A1 (fr) 1992-12-24
GB9209529D0 (en) 1992-07-01
AU4521897A (en) 1998-02-12
ATA900791A (de) 1996-06-15
ES2112865T5 (es) 2007-09-16
MX9203794A (es) 1992-07-01
FI922380L (fi) 1992-05-25
IL102726A0 (en) 1993-01-31
NZ244114A (en) 1995-06-27
CH681305A5 (enExample) 1993-02-26
BE1004226A5 (fr) 1992-10-13
ES2081742B1 (es) 1996-10-01
ES2081742A1 (es) 1996-03-01
HUT64601A (en) 1994-01-28
DE69128774T2 (de) 1998-06-04
AU716402B2 (en) 2000-02-24
US5644036A (en) 1997-07-01
GB2253397A (en) 1992-09-09
FI922824L (fi) 1992-06-17
GB9022547D0 (en) 1990-11-28
ZA926191B (en) 1993-04-16
MY136210A (en) 2008-08-29
FI922380A0 (fi) 1992-05-25
FI110003B (fi) 2002-11-15
AU649078B2 (en) 1994-05-12
PT99248A (pt) 1993-06-30
IE913560A1 (en) 1992-04-22
FR2668164B1 (enExample) 1995-04-14
ZA918259B (en) 1993-04-16
PT100988A (pt) 1994-02-28
AU2532192A (en) 1993-02-11
LU88122A1 (fr) 1993-03-15
KR100193314B1 (ko) 1999-06-15
TW283710B (enExample) 1996-08-21
PT99248B (pt) 1999-04-30
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
AU658926B2 (en) 1995-05-04
HU9202000D0 (en) 1992-10-28
KR920703108A (ko) 1992-12-17
BR1100358A (pt) 2000-03-28
ITRM910788A0 (it) 1991-10-16
JP2638680B2 (ja) 1997-08-06
EP0504363B2 (en) 2007-02-07
EP0504363B1 (en) 1998-01-21
EP0504363A1 (en) 1992-09-23
DK0504363T4 (da) 2007-05-29
CH681455A5 (enExample) 1993-03-31
CA2069481A1 (en) 1992-04-18
PT100988B (pt) 1999-08-31
NZ240247A (en) 1994-03-25
FI110002B (fi) 2002-11-15
GR3026588T3 (en) 1998-07-31
FR2668164A1 (fr) 1992-04-24
IL102726A (en) 2002-08-14
WO1992007084A1 (en) 1992-04-30
KR960015399B1 (ko) 1996-11-13
CA2069481C (en) 2003-07-29
IT1250064B (it) 1995-03-30
FI922824A0 (fi) 1992-06-17
AU7024294A (en) 1995-01-05
ES2112865T3 (es) 1998-04-16
DE69128774D1 (de) 1998-02-26
MY119030A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
IL102726A0 (en) Purified immunoglobulins,their preparation and pharmaceutical compositions containing them
EP0185034A4 (enExample)
CA1208130A (en) ULTRAPURIFICATION OF FACTOR VIII
AU4088685A (en) Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
EP0239565A3 (en) Method of and apparatus for separating proteins
IL88118A (en) Ion-exchange chromatographic method of purifying proteins
KR960009052B1 (en) Simultaneous preparation process of useful proteins from human urine
KR860008270A (ko) α-인터페론의 제조 및 정제 방법
Dimitrijevic et al. Purification and characterization of an estrogen-binding peroxidase from human fetuses
DENG PURIFICATION OF HUMAN INTERFERON-? BY ANTIBODY AFFINITY CHROMATOGRAPY
von Bahr-Lindström et al. Analytical and Preparative Applications of High-Performance Liquid Chromatography. Comparisons with Other Methods
SE8902230D0 (sv) Interferon purification process
JPS54138189A (en) Separation and purification of urokinase
FR2411202A1 (fr) Procede d'extraction et de purification de la globuline transporteur d'hormones thyroidiennes tbg
LESTER et al. Inhibition of Human Lymphocyte Transformation by Human α‐fetoprotein (HAFP): Studies on the Mode of HAFP Action and the Role of HAFP Polymorphism